Albert Bourla, Pfizer CEO (Michel Euler/AP Images, Pool)
May 31, 2023 05:58 PM EDTUpdated June 1, 11:02 AM
Pharma
FDA+

FDA ap­proves Pfiz­er’s RSV shot for old­er adults, tee­ing up a com­pet­i­tive $17B vac­cine mar­ket

Andrew Dunn

Senior Biopharma Correspondent

The FDA ap­proved Pfiz­er’s RSV vac­cine called Abrys­vo for old­er adults on Wednes­day, plac­ing an­oth­er Big Phar­ma on­to the com­mer­cial stage ahead of the next …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times